CSO Dr Roly Foulkes discusses importance of immune resetting at Biotrinity 2019

CSO Dr Roly Foulkes discusses importance of immune resetting at Biotrinity 2019

Stevenage, UK, 7 May 2019, Immune Regulation Limited (‘Immune Regulation’ or the ‘Company’) a biopharmaceutical company developing “first in class” immune-resetting therapies for asthma and other inflammatory diseases, announces that Dr. Roly Foulkes, Chief Scientific Officer, took part in a panel discussion titled “What’s New in Autoimmune Disease?” at the BioTrinity 2019 conference in London on 1 May 2019.

Alongside leading industry peers from Cambridge Immunology Network, Eli Lilly, M Ventures and UCL, Dr Foulkes discussed the importance of immune system resetting, potential targets for autoimmune drug development, priority autoimmune diseases for research and what biotechnology companies working in this space need to succeed.

Menu